My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Expression of FOXP3, CD68 and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma is Predictive of outcome. J Clin Oncol (2013) 31(2):256-62. PMID: 23045593
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA (2009) 106(15):6250-5. PMID: 19332800
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 118(7):2427-37. PMID: 18551193
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 112(2):394-7. PMID: 18434611
The research interest of my group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma. D'Avola A, Legrave N, Tajan M et al. J Clin Invest (2022) (2)
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Hayden PJ, Roddie C, Bader P et al. Ann Oncol (2022) 33(2) 259-275
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. Buske C, Dreyling M, Alvarez-Larrán A et al. ESMO Open (2022) 7(2) 100403
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial. Moreno C, Greil R, Demirkan F et al. Haematologica (2022) (2)
Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL Gagelmann N, Gribben J, Kröger N (2022) (10) 123-125
Educational Needs for Physicians Kröger N, Gribben J, Sánchez-Ortega I (2022) (10) 203-206
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019 Swan D, Hayden PJ, Eikema DJ et al. British Journal of Haematology (2022) (7)
Abstract LBA013: Phosphoproteomics reveals active drug targets on pathways of resistance and predicts response to midostaurin plus chemotherapy in FLT3 mutant-positive acute myeloid leukemia Nobre LV, Basanta CC, Pedicona SF et al. (2021) (10) lba013-lba013
Umbralisib and ublituximab: An upcoming regimen for chronic lymphocytic leukemia Gribben J Clinical Advances in Hematology and Oncology (2021) 19(7) 768-769
A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL) Palomba ML, Ghione P, Patel AR et al. Blood (2021) 138(10) 3543-3543For additional publications, please click here
Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove
I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.
In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.